Gain Therapeutics (GANX) Expected to Announce Earnings on Wednesday

Gain Therapeutics (NASDAQ:GANX) is anticipated to post its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Gain Therapeutics to post earnings of ($0.13) per share and revenue of $0.0330 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. On average, analysts expect Gain Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Gain Therapeutics Price Performance

Shares of NASDAQ:GANX opened at $1.87 on Wednesday. The company has a quick ratio of 6.63, a current ratio of 6.63 and a debt-to-equity ratio of 0.02. The company has a market cap of $79.76 million, a P/E ratio of -3.07 and a beta of 0.15. Gain Therapeutics has a 52 week low of $1.41 and a 52 week high of $4.34. The company has a 50-day moving average price of $2.16 and a 200 day moving average price of $2.39.

Institutional Investors Weigh In On Gain Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC acquired a new stake in shares of Gain Therapeutics during the 4th quarter valued at approximately $45,000. Engineers Gate Manager LP acquired a new stake in shares of Gain Therapeutics during the 4th quarter valued at approximately $47,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Gain Therapeutics during the 4th quarter valued at approximately $120,000. Marshall Wace LLP lifted its position in shares of Gain Therapeutics by 849.3% during the 4th quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock valued at $5,353,000 after acquiring an additional 1,487,186 shares during the period. Finally, State Street Corp lifted its position in shares of Gain Therapeutics by 72.9% during the 4th quarter. State Street Corp now owns 157,537 shares of the company’s stock valued at $507,000 after acquiring an additional 66,400 shares during the period. 11.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Gain Therapeutics in a research report on Friday, April 10th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Gain Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.